Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 14Carcinoma, Non-Small-Cell Lung 11Lung Neoplasms 9Pancreatic Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Head and Neck Neoplasms 7Colorectal Neoplasms 7Ovarian Neoplasms 6Neoplasm Metastasis 6Carcinoma, Hepatocellular 6Triple Negative Breast Neoplasms 5Urinary Bladder Neoplasms 4Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Biliary Tract Neoplasms 4Stomach Neoplasms 3Small Cell Lung Carcinoma 3Prostatic Neoplasms 3Lymphoma, Follicular 3Kidney Neoplasms 3Cholangiocarcinoma 3Carcinoma, Squamous Cell 3Carcinoma, Renal Cell 3Carcinoma 3Adenocarcinoma Of Esophagus 3Uterine Cervical Neoplasms 2Recurrence 2Oropharyngeal Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2Lymphoma, T-Cell, Cutaneous 2

Interventions

pembrolizumab 21lenvatinib 8Paclitaxel 5patritumab deruxtecan 3enfortumab vedotin 2belzutifan 2Tretinoin 2Surgical Procedures, Operative 2Oxaliplatin 2Leucovorin 2Irinotecan 2Fluorouracil 2Carboplatin 2Capecitabine 2tremelimumab 1trametinib 1poly ICLC 1epacadostat 1efineptakin alfa 1durvalumab 1dabrafenib 1Ramucirumab 1Radiotherapy 1Radiosurgery 1Radiation 1Pemetrexed 1Levoleucovorin 1Immunotherapy 1Histamine H2 Antagonists 1Histamine Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Parkinson Disease 4, Autosomal Dominant Lewy Body × durvalumab × Clear all
NCT02735239 2024-03-22

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

Ludwig Institute for Cancer Research

Phase 1/2 Completed
73 enrolled 18 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡